Sorbent Therapeutics Obtains $36,000,000 Series B Financing Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=bc10be59-c9a6-4efa-8c78-6195950fedee&Preview=1 -
Date
6/30/2011 -
Company Name
Sorbent Therapeutics -
Mailing Address
710 Lakeway Drive Sunnyvale, CA 94085 -
Company Description
Sorbent Therapeutics is a biopharmaceutical company focused on the development of adaptable non-absorbed polymeric drugs to satisfy unmet clinical needs in large markets such as End Stage Renal Disease (ESRD), Congestive Heart Failure (CHF), Chronic Kidney Disease (CKD), and Hypertension. -
Website
http://www.sorbentrx.com -
Transaction Type
Venture Equity -
Transaction Amount
$36,000,000 -
Transaction Round
Series B -
Proceeds Purposes
The financing will enable Sorbent to complete Phase 2 for its lead program in heart failure, CLP1001. -
M&A Terms
-
Venture Investor
Novartis Venture Fund -
Venture Investor
Sofinnova Ventures -
Venture Investor
ARCH Venture Partners -
Venture Investor
CMEA Ventures -
Venture Investor
AgeChem Venture Fund
